These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 24640618)

  • 1. Genetic gatekeepers: regulating direct-to-consumer genomic services in an era of participatory medicine.
    Palmer JE
    Food Drug Law J; 2012; 67(4):475-524, iii. PubMed ID: 24640618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Don’t Try This at Home: the FDA’s Restrictive Regulation of Home Testing Devices.
    Baird S
    Duke Law J; 2017 Nov; 67(2):383-426. PubMed ID: 29469551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RECONCEPTUALIZING CONSENT FOR DIRECT-TO-CONSUMER HEALTH SERVICES.
    Spector-Bagdady K
    Am J Law Med; 2015; 41(4):568-616. PubMed ID: 26863850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medical Marketing in the United States, 1997-2016.
    Schwartz LM; Woloshin S
    JAMA; 2019 Jan; 321(1):80-96. PubMed ID: 30620375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct-to-consumer genetic testing: good, bad or benign?
    Caulfield T; Ries NM; Ray PN; Shuman C; Wilson B
    Clin Genet; 2010 Feb; 77(2):101-5. PubMed ID: 19968666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct-to-consumer genetic testing: learning from the past and looking toward the future.
    Bair S
    Food Drug Law J; 2012; 67(4):413-33, ii. PubMed ID: 24640615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Consumers' views of direct-to-consumer genetic information.
    McBride CM; Wade CH; Kaphingst KA
    Annu Rev Genomics Hum Genet; 2010; 11():427-46. PubMed ID: 20690815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Should direct-to-consumer personalized genomic medicine remain unregulated?: a rebuttal of the defenses.
    Valles SA
    Perspect Biol Med; 2012; 55(2):250-65. PubMed ID: 22643762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 23andMe: a new two-sided data-banking market model.
    Stoeklé HC; Mamzer-Bruneel MF; Vogt G; Hervé C
    BMC Med Ethics; 2016 Mar; 17():19. PubMed ID: 27059184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Turning point or tipping point: new FDA draft guidances and the future of DTC advertising.
    Pitts PJ
    Health Aff (Millwood); 2004; Suppl Web Exclusives():W4-259-61. PubMed ID: 15452001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulating direct-to-consumer genetic testing: protecting the consumer without quashing a medical revolution.
    Gniady JA
    Fordham Law Rev; 2008 Apr; 76(5):2429-75. PubMed ID: 18546580
    [No Abstract]   [Full Text] [Related]  

  • 12. The federal regulation of prescription drug advertising and promotion.
    Kessler DA; Pines WL
    JAMA; 1990 Nov; 264(18):2409-15. PubMed ID: 2231998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Export of pharmaceuticals and medical devices under the federal Food, Drug & Cosmetic Act: FDA's striking change in interpretation post-Shelhigh.
    Basile EM; Tolomeo D; Gluck E
    Food Drug Law J; 2009; 64(1):149-69. PubMed ID: 19998744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct-to-consumer personal genome testing and cancer risk prediction.
    Bellcross CA; Page PZ; Meaney-Delman D
    Cancer J; 2012; 18(4):293-302. PubMed ID: 22846729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Attitudes about regulation among direct-to-consumer genetic testing customers.
    Bollinger JM; Green RC; Kaufman D
    Genet Test Mol Biomarkers; 2013 May; 17(5):424-8. PubMed ID: 23560882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility.
    American Society of Clinical Oncology
    J Clin Oncol; 2003 Jun; 21(12):2397-406. PubMed ID: 12692171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. American Society of Clinical Oncology policy statement: oversight of clinical research.
    American Society of Clinical Oncology
    J Clin Oncol; 2003 Jun; 21(12):2377-86. PubMed ID: 12721281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FDA's expanding postmarket authority to monitor and publicize food and consumer health product risks: the need for procedural safeguards to reduce "transparency" policy harms in the post-9/11 regulatory environment.
    Roller ST; Pippins RR; Ngai JW
    Food Drug Law J; 2009; 64(3):577-98. PubMed ID: 19999646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nutrigenomics and ethics interface: direct-to-consumer services and commercial aspects.
    Ries NM; Castle D
    OMICS; 2008 Dec; 12(4):245-50. PubMed ID: 19040371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct-to-consumer genomics on the scales of autonomy.
    Vayena E
    J Med Ethics; 2015 Apr; 41(4):310-4. PubMed ID: 24797610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.